Results 91 to 100 of about 131,342 (265)

Real‐World Use of Emicizumab in Patients With Acquired Haemophilia A: An Interim Safety Analysis of a Large‐Scale Post‑Marketing Surveillance Study

open access: yesHaemophilia, EarlyView.
ABSTRACT Introduction Acquired haemophilia A (AHA) is a rare autoimmune disorder where the development of autoantibodies to factor (F)VIII neutralise its function, leading to bleeding. Emicizumab has been approved for treating AHA in Japan. Aim This post‐marketing study was performed to primarily examine the use and safety of emicizumab, and indirectly
Midori Shima   +8 more
wiley   +1 more source

Non-infectious pulmonary complications of hematopoietic stem cell transplantation [PDF]

open access: yes, 2014
Noninfectious pulmonary complications of hematopoietic stem cell transplant are currently more prevalent than infectious complications. Unfortunately, the pathophysiology basis is not completely understood.
Baloglu, Orkun   +2 more
core   +1 more source

Risk factors for transplant-associated thrombotic microangiopathy and mortality in a pediatric cohort.

open access: yesBlood Advances, 2020
Transplant-associated thrombotic microangiopathy (TA-TMA) is a well-recognized complication of hematopoietic cell transplantation (HCT). Diagnosis is challenging and in the absence of a tissue biopsy, TA-TMA is provisionally diagnosed by meeting clinical
M. Schoettler   +7 more
semanticscholar   +1 more source

Glomerular plasmalemma vesicle‐associated protein‐1 as an endothelial remodelling marker complementing C4d in chronic active antibody‐mediated rejection

open access: yesHistopathology, EarlyView.
Glomerular plasmalemma vesicle‐associated protein‐1 (PV‐1/PLVAP) identifies dynamic endothelial remodelling in chronic active antibody‐mediated rejection (caABMR), complementing glomerular C4d, which reflects a static footprint of complement activation. Combined assessment of PV‐1 and C4d captures complementary dimensions of microvascular pathology and
Yuto Igarashi   +7 more
wiley   +1 more source

Thinking Beyond HLH: Clinical Features of Patients with Concurrent Presentation of Hemophagocytic Lymphohistiocytosis and Thrombotic Microangiopathy

open access: yesJournal of Clinical Immunology, 2020
Hemophagocytic lymphohistiocytosis (HLH) is a syndrome of excessive immune system activation driven mainly by high levels of interferon gamma. The clinical presentation of HLH can have considerable overlap with other inflammatory conditions. We present a
N. Gloude   +9 more
semanticscholar   +1 more source

Fostamatinib treatment for patients with antiphospholipid syndrome and low platelet count: A case series

open access: yes
British Journal of Haematology, EarlyView.
Ekaterina Balaian   +6 more
wiley   +1 more source

Comparative 3‐Year Allograft Outcomes for Recipients of Kidneys From SARS‐CoV‐2 NAT‐Positive Donors

open access: yesTransplant Infectious Disease, EarlyView.
In this retrospective single‐center study of 220 kidney transplants from SARS‐CoV‐2 NAT+, NAT+ with COVID as cause of death (CoV‐COD) and NATneg donors, we found no significant difference in rejection or kidney pathologies at 1 year, and death, graft loss, or eGFR at 3 years by CoV‐donor status.
Christine E. Koval   +5 more
wiley   +1 more source

Pulmonary tumor thrombotic microangiopathy presenting as recurrent syncope

open access: yesSAGE Open Medical Case Reports, 2020
Pulmonary tumor thrombotic microangiopathy is a rare condition in which embolization of tumor cells to the pulmonary arterioles causes fibrocellular intimal thickening and activation of the coagulation cascade resulting in pulmonary hypertension and ...
Constanza Burciaga Calderoni   +3 more
doaj   +1 more source

Dangerous drug interactions leading to hemolytic uremic syndrome following lung transplantation [PDF]

open access: yes, 2010
Background To report our experience of a rather uncommon drug interaction, resulting in hemolytic uremic syndrome (HUS). Methods Two consecutive cases of hemolytic uremic syndrome were diagnosed in our service.
Haralabos Parissis   +2 more
core   +2 more sources

Home - About - Disclaimer - Privacy